Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial

Persisting severe thrombocytopenia more than 6 weeks after allogeneic stem cell transplantation is a common problem associated with adverse prognosis. Peffault de Latour et al report the results of the first trial of the thrombopoietin mimetic, romiplostim, in this setting, demonstrating recovery of...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 135; no. 3; pp. 227 - 229
Main Authors Peffault de Latour, Régis, Chevret, Sylvie, Ruggeri, Anna Lisa, Suarez, Felipe, Souchet, Laetitia, Michonneau, David, Sicre de Fontbrune, Flore, Coman, Tereza, Dhedin, Nathalie, Rubio, Marie Thérèse, Nguyen, Stéphanie, Mohty, Mohamad, Socié, Gérard
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 16.01.2020
American Society of Hematology
Subjects
Adult
Aged
Cancer
Female
Follow-Up Studies
Hematologic Diseases - pathology
Hematologic Diseases - therapy
Hematopoietic Stem Cell Transplantation - adverse effects
Human health and pathology
Humans
Life Sciences
Male
Middle Aged
Prognosis
Receptors, Fc - therapeutic use
Recombinant Fusion Proteins - therapeutic use
Survival Rate
Thrombocytopenia - drug therapy
Thrombocytopenia - etiology
Thrombocytopenia - pathology
Thrombopoietin - therapeutic use
Online AccessGet full text

Cover

More Information
Summary:Persisting severe thrombocytopenia more than 6 weeks after allogeneic stem cell transplantation is a common problem associated with adverse prognosis. Peffault de Latour et al report the results of the first trial of the thrombopoietin mimetic, romiplostim, in this setting, demonstrating recovery of platelet counts in 18 of 24 patients.
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Feature-1
ObjectType-Correspondence-3
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.2019000358